mardi 2 mai 2017

Onco Actu du 2 mai 2017

1. Biologie

New model could speed up colon cancer research [MIT News]

2.10 Etiologie - Alcool

Study confirms link between alcohol consumption, breast cancer risk in black women [UNC Linberger]

4. Dépistage, diagnostic et pronostic

New Imaging Method May Predict Immunotherapy Response Early [AACR]

4.1 Dép., diag. & prono. - Prostate

With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer [Xconomy]

4.10 Dép., diag. & prono. - Poumon

ELCC 2017 Press Release: Men Need More Frequent Lung Cancer Screening Than Women [ESMO]

4.12 Biopsies liquides

Serial Analysis of Circulating Tumor Cells May Provide Biomarker Predictive of Lung Cancer Response to Crizotinib [AACR]

4.5 Dép., diag. & prono. - Colorectal

Follow-up colonoscopy cuts bowel cancer cases in some people [Cancer Research UK]

4.7 Dép., diag. & prono. - Col de l'utérus

The Pap smear: groundbreaking, lifesaving — and obsolete? [STAT]

5. Traitements

Overcoming cancer evolution with collateral sensitivity and drug holidays [EvMed Review]

5.12.6 Immunothérapies - AMM

Welcome Imfinzi: AstraZeneca crashes the checkpoint party late with a green light for durvalumab [EndPoints]

Durvalumab (Imfinzi) [FDA]

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy [BMS]

Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma [Genmab]

AstraZeneca immunotherapy wins first approval in bladder cancer [Reuters]

5.2 Pharma

Genmab Announces New Phase III Combination Study of Daratumumab in Multiple Myeloma [Genmab]

5.2.2 Pharma - Fusions & Acquisitions

Bristol-Myers drops option to buy HER2 cancer biotech [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

EMA and heads of national competent authorities discuss consequences of Brexit [EMA]

Scott Gottlieb And The Goldilocks Theory Of Bringing Change To The FDA [Health Affairs Blog]

5.3.4 Traitements - AMM (FDA, EMA)

U.S. FDA approves Novartis' leukemia treatment [Reuters]

Novartis bags FDA OK for Rydapt, adding a new chemo combo drug for AML [EndPoints]

Novartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) [Novartis]

FDA approves new combination treatment for acute myeloid leukemia [FDA]

Takeda Announces FDA Accelerated Approval of ALUNBRIG™ (brigatinib) [Takeda]

U.S. FDA approves Takeda's lung cancer drug as second-line treatment [Reuters]

Takeda gets a potential blockbuster bonus on $5B Ariad deal with FDA’s approval of brigatinib [EndPoints]

Takeda's Ariad deal pays off with blockbuster green light for Alunbrig [FiercePharma]

5.4 Traitements - Economie

Cancer Drugs Fund poor value for money, study finds [PharmaTimes]

What Is Maddening About Pharmaceutical Prices [Forbes]

6. Lutte contre les cancers

Waiting and watching with ‘Stage 0’ breast cancer put to nationwide test [Washington Post]

Defending Biomedical Science in an Era of Threatened Funding [JAMA]

6.10.1 Politiques (USA)

ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding [ASCO]

Taking a ride on the NIH budget rollercoaster [STAT]

The NIH Looks Trump-Proof [Bloomberg]

How science fares in the U.S. budget deal [Science]

ASCO Strongly Opposes AHCA in Current Form, Urges “No” Vote in House [ASCO]

Science wins reprieve in US budget deal [Nature]

Trump: Slash the health research budget. Congress: No. [Vox]

6.6 Publications

Nature Journals to Authors: Get Hip to ORCID [The Scientist]

Springer Nature announces new ORCID initiatives [Springer]

6.7.1 Bioinformatique

Deep Learning Is a Black Box, but Health Care Won’t Mind [MIT Technology Review]

6.7.3 DMP

Cancer patients in limbo as five hospitals suffer 'major' IT crash [The Telegraph]

6.9 Controverses

University of Utah health system CEO resigns after cancer center flap [STAT]

Breast surgeon Ian Paterson needlessly harmed patients [BBC News]

Software Eats the World, But Biology Eats It [In the Pipeline]